Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis

To evaluate the impact of tanezumab on health status, non-work activities, and work productivity in a pooled analysis of two large phase 3 osteoarthritis (OA) studies. Subcutaneous tanezumab (2.5 mg and 5 mg) was tested in double-blind, placebo-controlled, 16-week (NCT02697773) and 24-week (NCT02709...

Full description

Saved in:
Bibliographic Details
Published in:BMC musculoskeletal disorders 2022-02, Vol.23 (1), p.106-106, Article 106
Main Authors: Conaghan, Philip G, Abraham, Lucy, Viktrup, Lars, Cislo, Paul
Format: Article
Language:English
Subjects:
Absenteeism
Adult
Analgesics
Analysis
Antibodies, Monoclonal, Humanized
Arthritis
Care and treatment
Clinical trials
Contraindications
Daily activities
Diagnosis
Dose-Response Relationship, Drug
EQ-5D
Health aspects
Health Status
Humans
Monoclonal antibodies
Musculoskeletal diseases
Narcotics
Nerve growth factor
Nonsteroidal anti-inflammatory drugs
Osteoarthritis
Osteoarthritis, Knee
Pain
Pain Measurement
Patients
Placebos
Population
Productivity
Quality of life
Questionnaires
Risk factors
Sedentary behavior
Severity of Illness Index
Testing
Treatment Outcome
Work productivity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the impact of tanezumab on health status, non-work activities, and work productivity in a pooled analysis of two large phase 3 osteoarthritis (OA) studies. Subcutaneous tanezumab (2.5 mg and 5 mg) was tested in double-blind, placebo-controlled, 16-week (NCT02697773) and 24-week (NCT02709486) clinical trials in patients with moderate-to-severe OA of the hip or knee. At baseline and week 16, all patients completed EQ-5D-5L and the Work Productivity and Activity Impairment-OA (WPAI-OA) activity impairment item. Those currently employed also completed WPAI-OA work time missed, impairment while working, and overall work impairment items. Between-group differences in least squares (LS) mean changes from baseline at week 16 were tested using analysis of covariance. Of 1545 pooled patients, 576 were employed at baseline. Improvements in EQ-5D-5L index value at week 16 were significantly greater for the tanezumab 2.5-mg group (difference in LS means [95% confidence interval (CI), 0.03 [0.01, 0.05]; p = 0.0083) versus placebo. Percent improvements (95% CI) in activity impairment (- 5.92 [- 8.87, - 2.98]; p 
ISSN:1471-2474
1471-2474
DOI:10.1186/s12891-022-05029-x